Stiefel Laboratories Inc., a closely held pharmaceutical maker, is considering selling itself in a deal that could be worth several billion dollars, according to people familiar with the matter.
The potential sale has drawn interest from a number of major drug companies, including Johnson & Johnson, Novartis and GlaxoSmithKline, these people said.
WSJ
No comments:
Post a Comment